Platelet dysfunction in critically ill patients.

Area of Science:

• Critical Care Medicine
• Hematology
• Clinical Pathology

Background:

• Critically ill patients often experience coagulopathy.
• Thrombelastography Platelet Mapping (TEG-PM) assesses platelet function.
• Platelet dysfunction may contribute to adverse outcomes in critical illness.

Purpose of the Study:

• To evaluate the extent of platelet dysfunction in critically ill adult patients using TEG-PM.
• To investigate the impact of aspirin use on platelet function in this population.
• To explore the correlation between platelet dysfunction and clinical outcomes.

Main Methods:

• Retrospective study of 79 critically ill, non-trauma adult patients in a medical/surgical ICU.
• TEG-PM was used to measure maximal potential clot strength (MA), MA-arachidonic acid (MA-AA), and MA-adenosine diphosphate (MA-ADP).
• Patients were stratified based on aspirin use; exclusions included intracerebral hemorrhage and recent cardiac surgery.

Main Results:

• Overall maximal potential clot strength (MA) was normal in all patient groups.
• Maximal potential clot strength from arachidonic acid (MA-AA) and adenosine diphosphate (MA-ADP) stimulation were significantly reduced in critically ill patients, irrespective of anticoagulant use.
• MA-AA was further reduced in patients taking aspirin compared to those not on aspirin.

Conclusions:

• Inhibition of the arachidonic acid and adenosine diphosphate pathways is a frequent finding in critically ill patients.
• The clinical significance of this platelet dysfunction, particularly regarding bleeding risk and transfusion needs, warrants further investigation.